Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
GlobalRPh RX List - ZYLOPRIM
Product / population
Oral allopurinol; this source distinguishes gout initiation from cancer-therapy hyperuricemia. It is not an IV ALOPRIM regimen.
Renal method
eGFR, mL/min as printed, for gout initiation; separate cancer table uses CrCl
Source revision
Source revision date not established in selected retrieval.
Retrieved
2026-09-09
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Starting dose, maintenance dose and indication must remain separate
Retained GlobalRPh text includes older CrCl-based ceilings. The retrieved RX gout table specifies lower initiation doses without band-specific maxima; the 2020 ACR guideline supports monitored titration to target, including in CKD.
What to reconcile: Do not silently blend old ceilings, new starting doses or cancer-therapy dialysis rows. Reconcile the intended gout regimen, source date and renal measure with a clinician.
Gout initiation and cancer-associated hyperuricemia have different renal tables in the same label. The dialysis schedule belongs to the cancer indication, not a universal gout regimen.
What to reconcile: Select the indication first. An initial low gout dose is not an eGFR-specific maintenance ceiling.
GlobalRPh-hosted RX List · Oral allopurinol; this source distinguishes gout initiation from cancer-therapy hyperuricemia. It is not an IV ALOPRIM regimen.
Renal method: eGFR, mL/min as printed, for gout initiation; separate cancer table uses CrCl Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-09
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
For adult gout, the mirror's initial doses use eGFR in mL/min as printed: above 60, no modification; above 30 through 60, 50 mg daily; above 15 through 30, 50 mg every other day; 5-15, 50 mg twice weekly; below 5, 50 mg weekly. Increase by 50 mg/day at intervals of two to four weeks while monitoring kidney function and response. The source does not define a maximum dose for each eGFR band.
These are starting doses, not fixed lifetime ceilings. The source has a separate cancer-therapy table with different dosing and a dialysis row. Do not apply that row to gout or exchange eGFR and CrCl without reconciling the source method.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.